Latest Financial Position News

Atlas Pearls Ltd (ASX: ATP) faced a tough FY26 with revenue down 42% to $25.8 million and a net loss of $7.9 million, driven by lower pearl quality and softer market conditions. Despite this, the company seeded a record number of oysters and declared a fully franked final dividend of 0.45 cents per share.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

Future Generation Global's half-year profit fell sharply as its portfolio lagged global benchmarks, yet it boosted its fully franked interim dividend reflecting confidence in its income sustainability.

Tabcorp Holdings posted modest revenue growth and a sharp rise in net profit for FY26, while unveiling a major acquisition to accelerate its wagering technology transformation.

Gateway Mining has stretched its Cowza gold mineralisation to 4.5 kilometres, unveiling continuous high-grade zones and reinforcing the Yandal Project’s emerging gold camp potential. Celia South also shines with a standout 9.7g/t intercept, as RC drilling ramps up to test mineralisation depth.

Paladin Energy Ltd (ASX:PDN) reversed prior losses with a net profit of US$5.3 million in FY2026, driven by a strong ramp-up of uranium production at Namibia's Langer Heinrich Mine and regulatory progress at its Canadian Patterson Lake South Project.

Camplify Holdings slashed its net loss by 95% in FY26, posting a second-half profit driven by cost cuts and the MyWay Mutual insurance launch, setting a foundation for growth in FY27.

Fenix Resources reported a 131% jump in net profit to $12.47 million for FY26, driven by an 87% surge in revenue amid ongoing production ramp-up and infrastructure investments.

Duratec Limited (ASX:DUR) reported a 4.1% rise in net profit after tax to $23.8 million for FY26 on stable revenue, underpinned by a record $650.8 million order book and multiple strategic acquisitions expanding its service portfolio.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

NeuroScientific Biopharmaceuticals posted a $4.69 million loss for FY2026, driven by R&D ramp-up and clinical progress with its StemSmart™ platform, while halting independent development of its glaucoma drug EmtinB to pursue licensing deals.